Curis (NASDAQ:CRIS) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Curis (NASDAQ:CRIS) in a report published on Friday morning. The firm issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Curis in a research note on Tuesday, December 10th.

Curis Stock Down 3.3 %

Shares of NASDAQ:CRIS opened at $2.66 on Friday. Curis has a 52-week low of $2.57 and a 52-week high of $17.49. The stock has a market cap of $22.52 million, a price-to-earnings ratio of -0.34 and a beta of 3.49. The business has a 50-day moving average price of $3.12 and a 200-day moving average price of $3.97.

Institutional Trading of Curis

Several hedge funds and other institutional investors have recently bought and sold shares of CRIS. Squarepoint Ops LLC purchased a new stake in Curis in the 4th quarter worth approximately $35,000. Millennium Management LLC lifted its stake in shares of Curis by 92.6% in the 4th quarter. Millennium Management LLC now owns 25,557 shares of the biotechnology company’s stock valued at $78,000 after purchasing an additional 12,287 shares during the period. Focused Wealth Management Inc boosted its holdings in Curis by 9.5% during the fourth quarter. Focused Wealth Management Inc now owns 59,204 shares of the biotechnology company’s stock worth $181,000 after buying an additional 5,138 shares in the last quarter. Geode Capital Management LLC grew its position in Curis by 27.3% during the fourth quarter. Geode Capital Management LLC now owns 83,129 shares of the biotechnology company’s stock valued at $254,000 after buying an additional 17,820 shares during the period. Finally, Alyeska Investment Group L.P. purchased a new position in Curis in the fourth quarter valued at $607,000. 29.97% of the stock is owned by institutional investors and hedge funds.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.